Novo CEO dismisses price pressure on growing GLP-1 segment

Although Victoza yielded disappointing results in first quarter, and Novo Nordisk's GLP-1 portfolio is generally under pressure, CEO Lars Fruergaard Jørgensen denies that the segment is subject to increased competition or price pressure. The company has no influence on the underlying reasons, he says.

Photo: Ritzau Scanpix/ERH/Niels Hougaard

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles